Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. The subsidiary Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.
Company Details
- Employees
- 190
- Founded
- -
- Address
- 419 Davis Drive, Suite 100, Morrisville,nc 27560,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- liquidia.com
- HQ
- Morrisville, NC
Liquidia Corporation Questions
Liquidia Corporation's website is liquidia.com
Liquidia Corporation's LinkedIn profile is https://www.linkedin.com/company/liquidia-corporation
Liquidia Corporation has
190 employees.
View email and phone details for 190
employees at Liquidia Corporation.
Liquidia Corporation's industry is
Biotechnology Research
Liquidia Corporation's top competitors are
Humacyte,
Eli Lilly And Company,
Alnylam Pharmaceuticals,
Amgen,
Beam Therapeutics,
Fujifilm Biotechnologies,
United Therapeutics Corporation,
Vertex Pharmaceuticals,
Biogen,
Verona Pharma.
Liquidia Corporation's categories are Biotechnology Research
Liquidia Corporation's founding year is 2004
